Therapeutic bispecific antibody formats: a patent applications review (1994-2017)

Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies

(2017) Darko Skegro et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo

(2017) S Hipp et al.   LEUKEMIA

The making of bispecific antibodies

(2017) Ulrich Brinkmann et al.   mAbs

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

(2017) Johannes Oldenburg et al.   NEW ENGLAND JOURNAL OF MEDICINE

OP0201 Safety, Tolerability, and Functional Activity of MGD010, A Dart® Molecule Targeting CD32B and CD79B, Following A Single Dose Administration in Healthy Volunteers

(2016) N. Pandya et al.   ANNALS OF THE RHEUMATIC DISEASES

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck

(2016) Antonio Jimeno et al.   CANCER

Abstract CT050: A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors

(2016) Emiliano Calvo et al.   CANCER RESEARCH

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

(2016) M. Bacac et al.   CLINICAL CANCER RESEARCH

MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies

(2016) Liqin Liu et al.   CLINICAL CANCER RESEARCH

A first-in-man phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody OMP-305B83 in patients with previously treated solid tumors

(2016) A. Jimeno et al.   EUROPEAN JOURNAL OF CANCER

Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer

(2016) Peter B. Alexander et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Pharmacokinetics and Tolerability of a Dual Variable Domain Immunoglobulin ABT-981 Against IL-1α and IL-1β in Healthy Subjects and Patients With Osteoarthritis of the Knee

(2016) Matthew P. Kosloski et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial

(2016) C. Bodet-Milin et al.   JOURNAL OF NUCLEAR MEDICINE

Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity

(2016) Andrew D. Tustian et al.   mAbs

Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells

(2016) Katharine D. Grugan et al.   mAbs

The use of CrossMAb technology for the generation of bi- and multispecific antibodies

(2016) Christian Klein et al.   mAbs

MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer

(2016) G. Hernandez-Hoyos et al.   MOLECULAR CANCER THERAPEUTICS

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis

(2016) P. Bru nker et al.   MOLECULAR CANCER THERAPEUTICS

Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer

(2016) Glen Reid et al.   Epigenomics

Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model

(2016) Jennifer A. MacDiarmid et al.   PLoS One

A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma

(2015) Steven C. Kao et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

FDA Approval: Blinatumomab

(2015) D. Przepiorka et al.   CLINICAL CANCER RESEARCH

AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy

(2015) Jingjing Wu et al.   Journal of Hematology & Oncology

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+tumor cells

(2015) Uwe Reusch et al.   mAbs

Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases

(2015) Michela Silacci et al.   mAbs

Alternative molecular formats and therapeutic applications for bispecific antibodies

(2015) Christoph Spiess et al.   MOLECULAR IMMUNOLOGY

FDA approves first immunotherapy combo

(2015) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates

(2015) Gurunadh R. Chichili et al.   Science Translational Medicine

The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis

(2015) Maarten Van Roy et al.   ARTHRITIS RESEARCH & THERAPY

Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG

(2015) Nicolas Fischer et al.   Nature Communications

T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330

(2015) G S Laszlo et al.   Blood Cancer Journal

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys

(2015) Eric J. Smith et al.   Scientific Reports

ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells

(2014) Giovanna Bossi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

139 GBR1302: a BEAT® bispecific antibody for the treatment of HER2 positive cancers

(2014) A. Croset et al.   EUROPEAN JOURNAL OF CANCER

CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas

(2014) Michael D Oberst et al.   mAbs

The therapeutic monoclonal antibody market

(2014) Dawn M Ecker et al.   mAbs

Nanocell targeting using engineered bispecific antibodies

(2014) Karin Taylor et al.   mAbs

Clinical development success rates for investigational drugs

(2014) Michael Hay et al.   NATURE BIOTECHNOLOGY

A multifunctional bispecific antibody protects against Pseudomonas aeruginosa

(2014) A. DiGiandomenico et al.   Science Translational Medicine

Two-in-One antibodies with dual action Fabs

(2013) Charles Eigenbrot et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Targeting T cells to tumor cells using bispecific antibodies

(2013) Stanley R Frankel et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen

(2013) Ivan Correia et al.   mAbs

Improving biophysical properties of a bispecific antibody scaffold to aid developability

(2013) Thomas Spreter Von Kreudenstein et al.   mAbs

Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule

(2013) Clarissa G. Jakob et al.   mAbs

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange

(2013) A. F. Labrijn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens

(2012) Gregory L. Moore et al.   mAbs

Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies

(2012) Christian Klein et al.   mAbs

Generation, characterization and structural data of chymase binding proteins based on the human Fyn kinase SH3 domain

(2012) Daniel Schlatter et al.   mAbs

Dual targeting strategies with bispecific antibodies

(2012) Roland Kontermann   mAbs

Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens

(2012) M. Friedrich et al.   MOLECULAR CANCER THERAPEUTICS

Monoclonal TCR-redirected tumor cell killing

(2012) Nathaniel Liddy et al.   NATURE MEDICINE

A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model

(2012) Takehisa Kitazawa et al.   NATURE MEDICINE

Intellectual property protection

(2011) Ulrich Storz   mAbs

Neonatal Fc receptor and IgG-based therapeutics

(2011) Timothy T. Kuo et al.   mAbs

Engineering the variable region of therapeutic IgG antibodies

(2011) Tomoyuki Igawa et al.   mAbs

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

(2011) W. Schaefer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

(2010) Markus M. Heiss et al.   INTERNATIONAL JOURNAL OF CANCER

Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion

(2010) Syd Johnson et al.   JOURNAL OF MOLECULAR BIOLOGY

Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties

(2010) G. Wozniak-Knopp et al.   PROTEIN ENGINEERING DESIGN & SELECTION

SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies†

(2010) Jonathan H. Davis et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy

(2010) Robert M. Sharkey et al.   SEMINARS IN NUCLEAR MEDICINE

Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma

(2009) E. A. Rossi et al.   BLOOD

Therapeutic antibodies: successes, limitations and hopes for the future

(2009) Patrick Chames et al.   BRITISH JOURNAL OF PHARMACOLOGY

Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy

(2009) Daniel A. Vallera et al.   LEUKEMIA RESEARCH

Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo

(2009) Aran F Labrijn et al.   NATURE BIOTECHNOLOGY